Feature | Contrast Media Injectors | March 02, 2017 | By Jeff Zagoudis

Advances in Contrast Media Injector Technology

This article originally was published as an introduction to the Contrast Media Injectors comparison chart published in the March 2017 issue.

contrast media

With medical imaging use on the rise, contrast media use is expected to grow as well, according to a May 2016 report from market research firm GlobalData. According to the report, the global market value for contrast injectors was $830 million in 2015, and that number is expected to reach nearly $1.8 billion by 2022 — an increase of nearly $970 million in just seven years. The growth will largely be driven by increasing use of computed tomography (CT), magnetic resonance imaging (MRI) and angiography procedures, as well as increasing disease burdens, according to GlobalData.

In the United States, healthcare reform has been another major driver of innovation. Reform efforts such as the Medicare Access and CHIP Reauthorization Act (MACRA) are poised to alter the way clinicians are reimbursed, providing incentives for them to practice more efficient, value-based care and evaluating their performance based on the quality of care delivered. In the world of contrast injectors, this is spurring increased adoption of technologies like syringeless injectors, which can improve imaging exam efficiency, and contrast dose recording systems, which can serve as a mechanism for measuring quality of care. 

 

Syringeless Injectors 

Syringeless power injectors have emerged in recent years as a solution to reduce contrast media waste. The Joint Commission does not allow the reuse of unused doses from single-use syringe injectors, so this option gives facilities the opportunity to use contrast media as efficiently as possible. Syringeless injectors have also been demonstrated to reduce exam times, leading to increased patient throughput. A study published in the Journal of the American College of Radiology in 2012 compared the efficiency of a dual-syringe injector with a syringeless injector in 275 consecutive CT exams. The syringeless injector saved over 2 minutes per exam, resulting in an increased throughput of 2.6 patients per day.1 

The first syringeless injector on the U.S. market, Bracco’s CT Exprès 3-D, launched at the 2016 Radiological Society of North America (RSNA) annual meeting in November. The multi-dose delivery system is designed for multi-patient use to increase the number of scans clinicians can perform in a day. The system is used in combination with the Isovue Imaging Bulk Package (IBP) and saline (0.9 percent sodium chloride injection USP). IBP was recently defined by the United States Pharmacopeia as the only contrast medium container for multi-dose, multi-patient use directly in the radiology room. 

Bracco is releasing its SmartInjectCT Solution, a dual offering of EmpowerCTA+ Injector System and NEXO Contrast Management System, in February 2017. SmartInjectCT Solution helps automated compliance to dose documentation guidelines, has enterprise-wide protocol management, and fleet-wide advancement in automation and documentation. EmpowerCTA+ Injector System, launched in March 2015, is indicated for the vascular administration of contrast and flushing media in conjunction with computed tomography (CT) scanning of the body with an optional interface to a CT scanner and an optional calculator for glomerular filtration rate (GFR). The EmpowerCTA+ allows users to fully customize the injection experience for each patient with real-time variable flow rates, Saline Advance and Saline Jump; Saline Advance feature can be used to test vein patency before performing the injection, while Saline Jump may be used in the last contrast injection phase, causing the system to immediately stop injecting contrast medium and jump to the programmed saline injection phase.

Bracco’s EmpowerCTA+ systems are supported by the Nexo Contrast Management System, which automatically delivers all the injection information to a centralized server. This allows for enterprise-wide contrast dose management.

Guerbet launched its syringe-free injection system, FlowSens, in March 2014. Composed of a softbag injector and associated disposables, the system uses a hydraulic, syringe-free injector to deliver contrast media. It is compatible with the company’s ScanBag solution and any type of contrast agent available on the market.

 

Dose Recording Systems 

While medical imaging and contrast use are on the rise, several recent studies have raised concerns about potential lingering effects of contrast agents, particularly gadolinium. As a result, several vendors offer their own methods of recording contrast dose and sending the information directly to a picture archiving and communication system (PACS), electronic medical record (EMR) or other data storage system.  

Bracco’s EmpowerCTA systems are supported by the Nexo Contrast Dose monitoring solution, which automatically delivers all injection information to a centralized server. This allows for enterprise-wide injector management. According to Bracco, Nexo has the ability to capture four Improvement activity measures under the Merit-based Incentives Payment System (MIPS), one of the two new alternative reimbursement tracks offered under MACRA.

Medrad most recently released version 2.5 of the Radimetrics Enterprise Platform at RSNA 2014. The latest release of Radimetrics features more advanced contrast dose analytics, with new charts and data options to help identify repeat injections and issues associated with intravenous administration. The platform is integrated onto several of Medrad’s systems, including the MR Xperion. 

Mallinckrodt launched its own contrast dose monitoring solution, the OptiSync data management system, in the fall of 2014 to complement its OptiVantage dual-head CT contrast delivery system. Operators can access all patient and pharmaceutical information with the scan of a barcode, and injection data — including the patient, drug, dose and administration — is transmitted to HL7-based healthcare systems while patient records are automatically updated. This creates a shared facility database that can help users assess areas where they can reduce errors, increase productivity or improve efficiency.

 

Other Recent System Releases

In February 2016, Guerbet announced U.S. Food and Drug Administration (FDA) clearance for the OptiOne single-head contrast delivery system. OptiOne is manufactured by Liebel-Flarsheim, one of the companies Guerbet acquired in November 2015 when it purchased Mallinckrodt’s Contrast Media and Delivery Systems (CMDS) business. The entry-level single-head injector is designed for injection of radiopaque CT contrast agents into the vascular system. It uses a motor-driven syringe mechanism with microprocessor control of the flow rate, volume, pressure and timing. All operations are performed on the touch-screen console, and the system has the ability to accommodate prefilled or empty syringes. 

Reference

1.    Ma, X., Singh, A., Fay, J., Boland, G., et al. “Comparison of Dual-Syringe
    and Syringeless Power Injectors in Outpatient MDCT Practice:
    Impact on the Operator’s Performance, CT Workflow, and Operation
    Cost.” Journal of the American College of Radiology. Published
    Aug. 2012. 

Related Content

The Global Contrast Injectors Market will grow by $613.47M during 2020-2024, according to Technavio
News | Contrast Media Injectors | June 17, 2020
June 17, 2020 — Technavio has been monitoring the ...
The FDA has approved Lilly’s TAUVID (flortaucipir F 18 injection), a radioactive diagnostic agent, for PET imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease

Getty Images

News | Contrast Media | June 01, 2020
June 1, 2020 — TAUVID, a radioactive diagnostic agent, has been approved by the FDA for...
Researchers from Tokyo Metropolitan University have surveyed the amount of gadolinium found in river water in Tokyo. Gadolinium is contained in contrast agents given to patients undergoing medical magnetic resonance imaging (MRI) scans, and it has been shown in labs to become toxic when exposed to ultraviolet rays. The researchers found significantly elevated levels, particularly near water treatment plants, highlighting the need for new public policy and removal technologies as MRI become even more commonp

Samples were taken along rivers around Tokyo. Measurements of rare earth element quantities indicate a clearly elevated amount of gadolinium compared to that in natural shale. Graphics courtesy of Tokyo Metropolitan University

News | Magnetic Resonance Imaging (MRI) | May 26, 2020
May 26, 2020 — Researchers from Tokyo Metropolitan...
Gadolinium-based contrast agents

UT Dallas faculty members who collaborated with Dr. Jeremiah Gassensmith (center, back), associate professor of chemistry and biochemistry, include Dr. Lloyd Lumata (left, back), assistant professor of physics, and Dr. Steven Nielsen, associate professor of chemistry. Chemistry graduate students in Gassensmith’s lab include (from left, front) Oliva Brohlin, Arezoo Shahrivarkevishahi and Laurel Hagge.

News | Contrast Media | February 06, 2020
February 6, 2020 — University of Texas at Dallas researchers
This image is of an 80 kg woman with a newly diagnosed IDH-wildtype glioblastoma

This image is of an 80 kg woman with a newly diagnosed IDH-wildtype glioblastoma. The quarter dose image on the left was obtained after the administration of 4 ml of MultiHance. Subsequently, an additional 12 ml of MultiHance was administered and the cumulative full dose image in the center was obtained. The image on the right was rendered following artificial intelligence processing of the 4 ml image using eGad genetic algorithms. This image has the quality of triple dose gadolinium even though only one quarter dose gadolinium was given.

Feature | Contrast Media Injectors | January 30, 2020 | By Matthew Kuhn, M.D., FACR
Gadolinium-based contrast agents (...

Image courtesy of Guerbet

Feature | Contrast Media Injectors | January 30, 2020 | By Melinda Taschetta-Millane
Contrast media injector technology has seen several recent advances, such as cutting costs by reducing contrast waste
Gadolinium based contrast dye in brain MRI

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | January 17, 2020
January 17, 2020 — Bracco Diagnostics Inc., the U.